Shares in biotech group Xilio Therapeutics (XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie Inc. (ABBV). The two companies announced a collaboration and option-to ...

NNN REIT's current deal flow pipeline is expected to come in at tighter spreads, implying less accretion to the bottom line. There is also an insufficient margin of safety between an unbiased ...

Stay updated on market trends for XLO. Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? AbbVie and Xilio partner to develop tumor-activated immunotherapies.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Short interest in Xilio Therapeutics Inc (NASDAQ:XLO) decreased during the last reporting period, falling from 694.61K to 575.45K. This put 1.3% of the company's publicly available shares short.